Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) and Provectus Biopharmaceuticals (OTCMKTS:PVCT – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.
Profitability
This table compares Amicus Therapeutics and Provectus Biopharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amicus Therapeutics | -6.67% | -5.07% | -1.23% |
| Provectus Biopharmaceuticals | -1,374.19% | N/A | -792.87% |
Analyst Ratings
This is a summary of recent recommendations for Amicus Therapeutics and Provectus Biopharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amicus Therapeutics | 1 | 1 | 7 | 1 | 2.80 |
| Provectus Biopharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
Risk & Volatility
Amicus Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Provectus Biopharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Insider & Institutional Ownership
0.1% of Provectus Biopharmaceuticals shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 14.7% of Provectus Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Amicus Therapeutics and Provectus Biopharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amicus Therapeutics | $571.16 million | 4.78 | -$56.11 million | ($0.12) | -73.83 |
| Provectus Biopharmaceuticals | $620,000.00 | 48.81 | -$4.76 million | N/A | N/A |
Provectus Biopharmaceuticals has lower revenue, but higher earnings than Amicus Therapeutics.
Summary
Amicus Therapeutics beats Provectus Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
